Filipek-Gorzala J, Kwiecinska P, Szade A, Szade K
Front Oncol. 2024; 14:1308709.
PMID: 38440231
PMC: 10910019.
DOI: 10.3389/fonc.2024.1308709.
Ayukawa S, Kamoshita N, Maruyama T
Semin Immunopathol. 2024; 45(4-6):521-532.
PMID: 38411739
DOI: 10.1007/s00281-024-01001-0.
Carabano M, Liu T, Liu A, Lee J, Cheng L, Wang L
Am J Transl Res. 2023; 15(9):5642-5652.
PMID: 37854217
PMC: 10579009.
Lee M, Ratanachan D, Wang Z, Hack J, Adbulrahman L, Shamlin N
J Immunol. 2023; 211(4):693-705.
PMID: 37395687
PMC: 10435044.
DOI: 10.4049/jimmunol.2100793.
Chen B, Zhu H, Yang B, Cao J
Acta Pharm Sin B. 2023; 13(5):1976-1989.
PMID: 37250147
PMC: 10213805.
DOI: 10.1016/j.apsb.2022.11.005.
Pervasiveness of HLA allele-specific expression loss across tumor types.
Filip I, Wang A, Kravets O, Orenbuch R, Zhao J, Perea-Chamblee T
Genome Med. 2023; 15(1):8.
PMID: 36759885
PMC: 9912643.
DOI: 10.1186/s13073-023-01154-x.
HLA-DRB1: A new potential prognostic factor and therapeutic target of cutaneous melanoma and an indicator of tumor microenvironment remodeling.
Deng H, Chen Y, Wang J, An R
PLoS One. 2022; 17(9):e0274897.
PMID: 36129956
PMC: 9491554.
DOI: 10.1371/journal.pone.0274897.
: a prognostic biomarker associated with immune infiltration and immunotherapeutic response in head and neck squamous cell carcinoma.
Wei Z, Shen Y, Zhou C, Cao Y, Deng H, Shen Z
Bioengineered. 2022; 13(5):13784-13800.
PMID: 35712757
PMC: 9276048.
DOI: 10.1080/21655979.2022.2084254.
Engineering Cancer/Testis Antigens With Reversible Cationization to Evaluate Antigen Spreading.
Miyamoto A, Honjo T, Masui M, Kinoshita R, Kumon H, Kakimi K
Front Oncol. 2022; 12:869393.
PMID: 35600379
PMC: 9115381.
DOI: 10.3389/fonc.2022.869393.
Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study.
Kuusisalo S, Koivunen J, Iivanainen S
Cancers (Basel). 2022; 14(9).
PMID: 35565405
PMC: 9103509.
DOI: 10.3390/cancers14092276.
Implementing Logic Gates for Safer Immunotherapy of Cancer.
Savanur M, Weinstein-Marom H, Gross G
Front Immunol. 2021; 12:780399.
PMID: 34804073
PMC: 8600566.
DOI: 10.3389/fimmu.2021.780399.
Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application.
Miyashita M, Shimizu T, Ashihara E, Ukimura O
Int J Mol Sci. 2021; 22(16).
PMID: 34445615
PMC: 8396358.
DOI: 10.3390/ijms22168910.
Gastric Cancer Mesenchymal Stem Cells Inhibit NK Cell Function through mTOR Signalling to Promote Tumour Growth.
Guo S, Huang C, Han F, Chen B, Ding Y, Zhao Y
Stem Cells Int. 2021; 2021:9989790.
PMID: 34306099
PMC: 8263240.
DOI: 10.1155/2021/9989790.
Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy.
Yokota C, Kagawa N, Takano K, Chiba Y, Kinoshita M, Kijima N
Cancer Immunol Immunother. 2021; 71(1):189-201.
PMID: 34089373
PMC: 10991314.
DOI: 10.1007/s00262-021-02954-z.
Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
Shaver K, Croom-Perez T, Copik A
Front Immunol. 2021; 12:679117.
PMID: 33995422
PMC: 8115550.
DOI: 10.3389/fimmu.2021.679117.
Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis.
Iafolla M, Yang C, Chandran V, Pintilie M, Li Q, Bedard P
JNCI Cancer Spectr. 2021; 5(1).
PMID: 33554038
PMC: 7853183.
DOI: 10.1093/jncics/pkaa115.
Determinants of Resistance to Checkpoint Inhibitors.
Tran L, Theodorescu D
Int J Mol Sci. 2020; 21(5).
PMID: 32111080
PMC: 7084564.
DOI: 10.3390/ijms21051594.
Cancer immune escape: MHC expression in primary tumours versus metastases.
Garrido F, Aptsiauri N
Immunology. 2019; 158(4):255-266.
PMID: 31509607
PMC: 6856929.
DOI: 10.1111/imm.13114.
Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients.
Yoo S, Keam B, Ock C, Kim S, Han B, Kim J
Sci Rep. 2019; 9(1):7680.
PMID: 31118488
PMC: 6531443.
DOI: 10.1038/s41598-019-44206-2.
Immunogenicity of Tumor Initiating Stem Cells: Potential Applications in Novel Anticancer Therapy.
Khandekar D, Amara S, Tiriveedhi V
Front Oncol. 2019; 9:315.
PMID: 31106150
PMC: 6494937.
DOI: 10.3389/fonc.2019.00315.